Cargando…
Immune-Mediated Hepatitis During Immune Checkpoint Inhibitor cancer Immunotherapy: Lessons From Autoimmune Hepatitis and Liver Immunology
Immune checkpoint inhibitors (ICI) are being increasingly used to successfully treat several types of cancer. However, due to their mode of action, these treatments are associated with several immune-related adverse events (irAEs), including immune-mediated autoimmune-like hepatitis in 5 to 10% of c...
Autores principales: | Hercun, Julian, Vincent, Catherine, Bilodeau, Marc, Lapierre, Pascal |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9280269/ https://www.ncbi.nlm.nih.gov/pubmed/35844534 http://dx.doi.org/10.3389/fimmu.2022.907591 |
Ejemplares similares
-
Novel Immunotherapies for Autoimmune Hepatitis
por: Cassim, Shamir, et al.
Publicado: (2017) -
Type 2 autoimmune hepatitis: Genetic susceptibility
por: Lapierre, Pascal, et al.
Publicado: (2022) -
Successful treatment of severe immune checkpoint inhibitor associated autoimmune hepatitis with basiliximab: a case report
por: Zarrabi, Maiah, et al.
Publicado: (2023) -
Autoimmune Hepatitis: Tolerogenic Immunological State During Pregnancy and Immune Escape in Post-partum
por: Bozward, Amber G., et al.
Publicado: (2020) -
Long-Term Follow-Up into Adulthood of Pediatric-Onset Primary Sclerosing Cholangitis and Autoimmune Sclerosing Cholangitis
por: Hercun, Julian, et al.
Publicado: (2022)